This 2014 state-of-the-art review synthesizes outcomes from major international cooperative osteosarcoma groups (COSS, COG, EOI, SSG, ISG, SFOP) to answer where high-grade osteosarcoma treatment stands after decades of multiagent chemotherapy development, and what challenges remain.
When counseling an osteosarcoma patient, use tumor location and histologic necrosis at resection as your primary prognostic anchors: extremity localized disease with good chemo response (≥90% necrosis) offers the best survival (70–80% 5-year EFS), while axial location, metastatic presentation, or poor histologic response each substantially worsen prognosis and should shift the conversation accordingly.
In eligible patients under 30 with non-metastatic disease, mifamurtide carries EMA approval as an add-on to chemotherapy based on a survival benefit in the COG INT-0133 trial.
This 2014 state-of-the-art review synthesizes outcomes from major international cooperative osteosarcoma groups (COSS, COG, EOI, SSG, ISG, SFOP) to answer where high-grade osteosarcoma treatment stands after decades of multiagent chemotherapy development, and what challenges remain.
When counseling an osteosarcoma patient, use tumor location and histologic necrosis at resection as your primary prognostic anchors: extremity localized disease with good chemo response (≥90% necrosis) offers the best survival (70–80% 5-year EFS), while axial location, metastatic presentation, or poor histologic response each substantially worsen prognosis and should shift the conversation accordingly.
In eligible patients under 30 with non-metastatic disease, mifamurtide carries EMA approval as an add-on to chemotherapy based on a survival benefit in the COG INT-0133 trial.